Public Expectations and Reality of Stem Cell Therapies Translation
By Alexey Bersenev,
Cell Trials
| 12. 07. 2012
Needless to say how much stem cell topic is overhyped today. Just turn on TV or radio and look at local newspaper or Internet –
stem cells are everywhere! The public opinion and perception of stem cell research and therapy is based almost entirely on media reporting. But how close/ far this perception from the reality? Many professionals can speculate that this gap is big. But do we have a data?
Tania Bubela just published a
study, which indicates that
public belief and optimism for stem cell research and translation is largely unjustified and even delusional. This study is very unique and important! We as a field can learn a lot from it!
Our goal is to uncover the nature of the biases in the public discourse on stem cell research that separates fact from fiction. This is the first step to creating better communication strategies among the clinical research community and the public, patients, and policy makers.
They measured public expectation by media coverage and compare it with clinical trials data. Media coverage data were retrieved...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...